- Schering AG has signed a licensing agreement with Teijin Ltd ofJapan for the rights to co-develop Schering's thrombolytic agent, desmodus salivary plasminogen activator, for the treatment of acute mycocardial infarction and stroke. In Phase I and IIa trials, DSPA has been shown to be more effective, more specific and safer than other thrombolytic agents on the market, says the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze